drugset / Trial / NCT00882999
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
RandomizedParallel-groupDouble-blindTreatment
Summary
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
Timeline
- Start
- 2009-04
- Primary completion
- 2011-02
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tabalumab | Monoclonal antibody | 4 mg | Other |
| Subject | Tabalumab | Monoclonal antibody | 12 mg | Other |
| Subject | Tabalumab | Monoclonal antibody | 40 mg | Other |
| Subject | Tabalumab | Monoclonal antibody | 120 mg | Other |